295 related articles for article (PubMed ID: 31590328)
1. From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights.
Anesi A; Generali L; Sandoni L; Pozzi S; Grande A
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590328
[TBL] [Abstract][Full Text] [Related]
2. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.
Williams DW; Lee C; Kim T; Yagita H; Wu H; Park S; Yang P; Liu H; Shi S; Shin KH; Kang MK; Park NH; Kim RH
Am J Pathol; 2014 Nov; 184(11):3084-93. PubMed ID: 25173134
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.
Vermeer JA; Renders GA; Everts V
Curr Osteoporos Rep; 2016 Oct; 14(5):219-25. PubMed ID: 27474028
[TBL] [Abstract][Full Text] [Related]
4. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
5. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
6. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
[TBL] [Abstract][Full Text] [Related]
7. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors.
Vermeer JA; Jansen ID; Marthi M; Coxon FP; McKenna CE; Sun S; de Vries TJ; Everts V
Bone; 2013 Nov; 57(1):242-51. PubMed ID: 23962725
[TBL] [Abstract][Full Text] [Related]
8. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
9. RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.
Aghaloo TL; Cheong S; Bezouglaia O; Kostenuik P; Atti E; Dry SM; Pirih FQ; Tetradis S
J Bone Miner Res; 2014 Apr; 29(4):843-54. PubMed ID: 24115073
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
12. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.
Elsayed R; Abraham P; Awad ME; Kurago Z; Baladhandayutham B; Whitford GM; Pashley DH; McKenna CE; Elsalanty ME
Bone; 2018 May; 110():141-149. PubMed ID: 29408511
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression.
Nakagawa T; Ohta K; Uetsuki R; Kato H; Naruse T; Murodumi H; Yokoyama S; Sakuma M; Ono S; Takechi M
Biochem Genet; 2020 Jun; 58(3):473-489. PubMed ID: 32274606
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
Neale SD; Smith R; Wass JA; Athanasou NA
Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
[TBL] [Abstract][Full Text] [Related]
15. Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.
Wehrhan F; Gross C; Creutzburg K; Amann K; Ries J; Kesting M; Geppert CI; Weber M
J Transl Med; 2019 Mar; 17(1):69. PubMed ID: 30832685
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2.
Nakagawa T; Ohta K; Kubozono K; Ishida Y; Naruse T; Takechi M; Kamata N
Arch Oral Biol; 2015 Apr; 60(4):557-65. PubMed ID: 25601046
[TBL] [Abstract][Full Text] [Related]
17. Osteoclast culture and resorption assays.
Bradley EW; Oursler MJ
Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
[TBL] [Abstract][Full Text] [Related]
18. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
19. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
20. A new osteoclastogenesis pathway induced by cancer cells targeting osteoclast precursor cells.
Wada A; Tsuchiya M; Ozaki-Honda Y; Kayamori K; Sakamoto K; Yamaguchi A; Ikeda T
Biochem Biophys Res Commun; 2019 Jan; 509(1):108-113. PubMed ID: 30578079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
